Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027
CMRAW
CMRAW was delisted on the 15th of November, 2023.
14 hedge funds and large institutions have $219K invested in Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 5 closing their positions.
26% less funds holding
Funds holding: 19 → 14 (-5)
32% less capital invested
Capital invested by funds: $323K → $219K (-$104K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$25K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$10K |
| 3 |
ACG
Aventail Capital Group
New York
|
-$4K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$1K |
CMRAW Hedge Fund Activity: Q4 2022 in Review
14 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 (CMRAW) for Q4 2022, worth a combined $219K — down 32% from $323K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CMRAW and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Boothbay Fund Management, exiting entirely with an estimated $25K sold.
- 14 institutional investors held Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 (CMRAW) as of Q4 2022, down from 19 in Q3 2022.
- Funds reported $219K of Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 stock for Q4 2022, down 32% quarter-over-quarter.
- 0 funds opened new Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 positions in Q4 2022 and 5 closed out, a net change of -5 holders.
- The largest Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 seller in Q4 2022 was Boothbay Fund Management, an estimated $25K sold.
Based on aggregated 13F filings for Q4 2022.